Sign in
Not yet taking people in United StatesPhase 3

Rapid Acceleration Process for Intensive Treatment of PTSD in 5 Days

Key facts

Who runs it
VA Office of Research and Development
Where
Palo Alto and Providence, United StatesSee the 2 sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
90 people, planned
Started
16 Nov 2026
Expected to end
6 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transcranial magnetic stimulation
  • Sham transcranial magnetic stimulation
Record updated
5 October 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Diagnosis of chronic post-traumatic stress disorder (PTSD), meeting DSM-5 criteria
  • Eligible Veterans
  • Symptomatic despite ongoing stable treatment (medications, psychotherapy, etc.) for at least 6 weeks before study procedures
  • Ongoing medications and psychotherapy will be allowed to continue unchanged during the study
  • For safety, participants must meet established screening criteria for magnetic resonance imaging (MRI); This is implemented as a conservative measure given the novel application of TBS in this population since MRI involves magnetic fields at a similar intensity to those emitted from the stimulation coil; These measures require a patient not to have the following (unless MRI-safe):; A cardiac pacemaker; implanted device (deep brain stimulation) or metal in the brain; cervical spinal cord; upper thoracic spinal cord
  • Willingness to participate in a clinical trial for approximately 4 to 6 months (consisting of a treatment phase with a 4-month follow-up period)
  • Veterans must also be willing and able to comply with all study-related procedures and visits and be capable of independently reading and understanding information materials and providing written informed consent
  • Sufficient visual and auditory acuity to allow neuropsychological testing

Who cannot take part

  • Psychiatric Exclusions
  • Primary psychotic disorder, bipolar I disorder, and greater than moderate substance use disorder (within the last month, excluding nicotine/caffeine, assessed by a urine drug screen as indicated), determined by the Mini International Neuropsychiatric Interview (MINI)
  • The presence of any other condition or circumstance that, in the opinion of the investigator team, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments; Medical Exclusions
  • History of neurological disorder (e.g., multiple sclerosis, seizure disorder, etc.) or systemic illness affecting central nervous system (CNS) function (e.g., liver failure, kidney failure, congestive heart failure, metastatic cancer) or that could meaningfully impact cortical excitability
  • Acute illness or unstable chronic illness, e.g., history of severe liver disease (cirrhosis, esophageal varices, ascites, portal hypertension, hepatic encephalopathy)
  • Have a mass lesion, cerebral infarct, or other neuroanatomical abnormality located at the transcranial magnetic stimulation (TMS) treatment site (DLPFC); a lifetime history of a) seizure disorder b) primary or secondary central nervous system (CNS) tumors c) stroke or d) cerebral aneurysm
  • Active suicidal intent or plan, as detected on screening instruments or in the investigator team's opinion, is likely to attempt suicide within 6 months
  • Pregnant or breastfeeding and planning to become pregnant within the next 3 months
  • Greater than mild traumatic brain injury (following VA/DoD definitions)
  • Inability to read, unable to verbalize understanding, and voluntarily sign the Informed Consent

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, United StatesContact: Geoffrey W Goodale, BSNot yet recruiting
  • Providence VA Medical Center, Providence, RIProvidence, United StatesContact: Noah S Philip, MDNot yet recruiting

About the trial

What the trial wants to find out

Veterans with posttraumatic stress disorder (PTSD) need more effective treatments. Existing options can have limited adherence and can be very time-consuming. As such, alternative interventions are needed. Transcranial magnetic stimulation (TMS) has been FDA-cleared for depression since 2008 and has recently been cleared to treat smoking cessation and obsessive-compulsive disorder. It has demonstrated promise for reducing PTSD symptom severity but standard TMS has a significant time requirement. This study will compare an accelerated 5-day form of TMS versus sham for PTSD, characterizing efficacy and durability. This project will provide important information that can be implemented in the near term for Veterans with PTSD.

The 2 groups in the trial

  • Active TMSExisting treatment, for comparison

    Active transcranial magnetic stimulation

    Treatment: Transcranial magnetic stimulation

  • Sham TMSSham treatment, for comparison

    Non-active/sham transcranial magnetic stimulation

    Treatment: Sham transcranial magnetic stimulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
RAPID5: Rapid Acceleration Process for Intensive Treatment of PTSD in 5 Days
Criteria questions
Built from NCT07167940, who can take part
Record updated
5 October 2026